Wegovy

Wegovy

Product

by Novo Nordisk

Heard in 32 episodes across 24 shows since Jun 2026

Wegovy is a brand name for semaglutide, an anti-obesity medication developed by Novo Nordisk for chronic weight management. Administered as a weekly subcutaneous injection, it acts as a GLP-1 receptor agonist to regulate appetite and food intake.

Learn more
Discussed inMarkets43%AI & Tech14%Health & Science14%Politics14%

Episodes

32
across 24 shows

This week

0
episodes on 0 shows

Expert statements

1
1 negative

Share of the conversation

Mentions of Wegovy per 1,000 mentions of anything, 7-day rolling, across the podcasts PodLume Trends follows.

0.0‰0.1‰0.2‰0.3‰Jul 11Aug 2Aug 25Sep 16Oct 8
Show the data
DayShare (7-day)Mentions
Aug 50.16‰1
Aug 120.04‰1
Aug 130.07‰1
Aug 140.09‰1
Aug 160.12‰1
Aug 170.16‰1
Aug 180.19‰1
Aug 210.21‰3
Aug 240.18‰1
Aug 310.03‰1
Sep 10.06‰1
Sep 20.10‰1
Sep 30.12‰1
Sep 40.16‰1
Sep 80.14‰1
Sep 110.07‰1
Sep 130.14‰2
Sep 210.06‰2
Sep 220.08‰1
Sep 250.11‰1

The full trend: rank, tone and why it is trending →

What experts have said about Wegovy

1 statement · 1 negative

  1. Chloe MelleyNegativeAug 5, 2026· Stock Movers

    Wegovy sales disappointed investors by failing to meet expectations.

    “the sales of its weight loss pill disappointed investors”

    Listen at 1:14

    Open the episode · Novo Nordisk Drops, Next Jumps, Infineon Falls
Filter the statements →

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.

Episodes

32 episodes featuring Wegovy, newest first

See all 32 episodes →